Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DKYL | ISIN: US07782B1044 | Ticker-Symbol: D01
Frankfurt
31.03.25
08:05 Uhr
60,50 Euro
-0,50
-0,82 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BELITE BIO INC ADR Chart 1 Jahr
5-Tage-Chart
BELITE BIO INC ADR 5-Tage-Chart

Aktuelle News zur BELITE BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiBelite Bio stock target raised to $80 at Benchmark1
21.03.BELITE BIO, INC - S-8, Securities to be offered to employees in employee benefit plans1
18.03.Belite Bio Analysts See Potential For Stock Gains With Progress In Key Trials2
18.03.Belite Bio stock holds $100 target post-results1
BELITE BIO Aktie jetzt für 0€ handeln
17.03.Belite Bio GAAP EPS of -$0.32 misses by $0.011
17.03.Belite Bio, Inc Q4 Loss Increases, Misses Estimates1
17.03.BELITE BIO, INC - 6-K, Report of foreign issuer-
17.03.Belite Bio, Inc: Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website1
17.03.Belite Bio, Inc: Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update69Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal Phase 3 trial in adolescent Stargardt 1 (STGD1) subjects, proceed without...
► Artikel lesen
11.03.Belite Bio, Inc: Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results1
27.02.BELITE BIO, INC - 6-K, Report of foreign issuer-
27.02.Belite Bio, Inc: Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects101An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, maintaining the sample size at 104 subjects following a planned...
► Artikel lesen
06.02.BELITE BIO, INC - 6-K, Report of foreign issuer-
06.02.Belite Bio to raise $15M via direct offering4
06.02.Belite Bio, Inc: Belite Bio Announces Registered Direct Offering of $15 Million1
27.01.Belite Bio files for automatic mixed securities shelf1
30.11.24Belite Bio (NASDAQ:BLTE) Shares Down 3.4% - Time to Sell?1
16.11.24Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Decreases By 13.5%2
14.11.24Belite Bio stock soars to all-time high of $84.2 amid robust gains1
14.11.24Belite Bio-Aktie erreicht Rekordhoch von 84,20 US-Dollar2
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1